Division of Nephrology, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Centre, Postbus 96002300, RC Leiden, Netherlands.
Nat Rev Nephrol. 2013 Dec;9(12):747-53. doi: 10.1038/nrneph.2013.152. Epub 2013 Aug 13.
The ageing population and the increasing prevalence of noncommunicable diseases such as diabetes and hypertension have led to an increased prevalence of chronic kidney disease. The generation of de novo kidney tissue from embryonic tissue and stem cells using tissue engineering approaches is being explored as an alternative to renal replacement therapy for treating the disease. It is, however, becoming clear that resident cells can not only induce fibrotic repair, but can also restore damaged kidney tissue. Mobilizing this innate capacity of the kidney to regenerate is of particular interest in the prevention of irreversible kidney failure. A novel concept is that the interaction of interstitial stromal cells with the local immune system may regulate tissue homeostasis and the balance between tissue repair and fibrosis. Mesenchymal stromal cells (MSCs), in particular, may enhance the intrinsic reparative capabilities of the kidney. This Perspectives article considers the innate regenerative potential of the kidney in the context of ongoing studies of MSC therapy.
人口老龄化和糖尿病、高血压等非传染性疾病的患病率不断上升,导致慢性肾脏病的患病率也有所增加。利用组织工程方法从胚胎组织和干细胞中生成新的肾脏组织,正被探索作为治疗这种疾病的肾脏替代疗法的替代方法。然而,越来越明显的是,固有细胞不仅可以诱导纤维化修复,还可以修复受损的肾脏组织。动员肾脏的这种内在再生能力对于预防不可逆转的肾衰竭特别有意义。一个新的概念是,间质基质细胞与局部免疫系统的相互作用可能调节组织内稳态以及组织修复和纤维化之间的平衡。间充质基质细胞(MSCs)尤其可能增强肾脏的内在修复能力。本文从正在进行的 MSC 治疗研究的角度出发,探讨了肾脏的固有再生潜力。